CDK8抑制诱导Mediator滞留并损害尤文肉瘤EWSR1::FLI1转录程序
本研究利用患者来源细胞系中的内源性EWSR1::FLI1靶基因报告系统进行高通量表型筛选,发现CDK8抑制剂(包括新型吡啶咪唑)可改变EWSR1::FLI1靶基因转录,且CDK8优先与EWSR1::FLI1共定位于单一GGAA DNA结合基序。通过CRISPR筛选、生化研究和染色质分析,揭示CDK8抑制剂通过诱导CDK8激酶模块和Mediator复合物在染色质上的分子滞留(功能获得机制)抑制尤文肉瘤细胞增殖。该机制提示转录调控复合物动态受损可能成为转录因子剂量敏感型癌症的脆弱点。
要点
- CDK8抑制剂可改变尤文肉瘤EWSR1::FLI1靶基因转录。
- CDK8优先与EWSR1::FLI1共定位于单一GGAA基序。
- CDK8抑制剂通过诱导Mediator滞留的功能获得机制抑制增殖。
核心结论
- CDK8抑制剂通过诱导CDK8激酶模块和Mediator复合物在染色质上的分子滞留,损害EWSR1::FLI1转录程序并抑制尤文肉瘤细胞增殖。
研究设计与样本
- 利用患者来源细胞系中的内源性EWSR1::FLI1靶基因报告系统进行高通量表型筛选,并结合 pooled CRISPR 筛选、生化研究和染色质分析。
主要发现
- CDK8抑制剂(包括新型吡啶咪唑)改变了EWSR1::FLI1靶基因的转录。
- CDK8与EWSR1::FLI1优先共定位于单一GGAA DNA结合基序。
- CDK8抑制剂通过功能获得机制诱导CDK8激酶模块和Mediator复合物在染色质上滞留,从而抑制尤文肉瘤细胞增殖。
临床怎么用
- CDK8抑制剂可能作为靶向EWSR1::FLI1转录程序的策略用于尤文肉瘤治疗。
- 转录调控复合物动态受损可能是转录因子剂量敏感型癌症的脆弱点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ewing sarcoma is characterized by a chromosomal translocation resulting in the fusion protein EWSR1::FLI1. We utilize endogenous EWSR1::FLI1 target gene reporters in patient-derived cell lines to perform a high-throughput phenotypic screen to identify small molecules that impair the EWSR1::FLI1 transcriptional program. We discovered that inhibitors of cyclin-dependent kinase 8 (CDK8), including a novel pyridyl imidazole, altered transcription of EWSR1::FLI1 target genes and CDK8 co-localized with EWSR1::FLI1 preferentially on single GGAA DNA binding motifs. Using pooled CRISPR screening, biochemical studies, and chromatin profiling, we discovered that CDK8 inhibitors suppressed proliferation of Ewing sarcoma cells through a gain-of-function mechanism by inducing molecular trapping of the CDK8 kinase module and Mediator complex on chromatin. This mechanism has implications for the development of small molecules to target transcription and suggests that impairment of transcriptional regulatory complex dynamics might serve as a vulnerability in cancers in which the dominant oncogenes act as dosage-sensitive transcription factors.
引用
- McGinnis JH, Wang S, O'Hara RA, et al. CDK8 inhibition induces Mediator trapping and impairment of the EWSR1::FLI1 transcriptional program in Ewing sarcoma. Cancer Discov. 2026. PMID: 42447057. doi:10.1158/2159-8290.CD-25-1336
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。